

Global COVID-19 Inactivated Vaccine Market 2022 by Company, Regions, Type and Application, Forecast to 2028

<https://marketpublishers.com/r/GA5C7FA4A77DEN.html>

Date: March 2022

Pages: 121

Price: US\$ 3,480.00 (Single User License)

ID: GA5C7FA4A77DEN

Abstracts

The COVID-19 Inactivated Vaccine market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.

According to our latest research, the global COVID-19 Inactivated Vaccine market size will reach USD million in 2028, growing at a CAGR of % over the analysis period.

Global key companies of COVID-19 Inactivated Vaccine include Inovio Pharmaceuticals, Takis Biotech (Evvivax), Zydus Cadila, Codagenix, Inc., and GeoVax, Inc., etc. In terms of revenue, the global top four players hold a share over % in 2021.

Market segmentation

COVID-19 Inactivated Vaccine market is split by Type and by Application. For the period 2012-2028, the growth among segments provide accurate calculations and forecasts for revenue by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.

Market segment by Type, covers

In Clinical Trials

Out-of-Clinical Trials

Market segment by Application, can be divided into

Hospital

Clinic

Other

Market segment by players, this report covers

Inovio Pharmaceuticals

Takis Biotech (Evvivax)

Zydus Cadila

Codagenix, Inc.

GeoVax, Inc.

Bravovax

Janssen Pharmaceutical Companies

Altimune

Vaxart

CanSino Biologics

ExpreS2ion Biotechnologies ApS

Clover Biopharmaceuticals

GSK

Vaxil Bio Ltd.

Generex

Novavax, Inc.

Sanofi Pasteur

Baylor

iBio, Inc.

Moderna, Inc.

Curevac

ImmunoPrecise

Market segment by regions, regional analysis covers

North America

Europe

Asia-Pacific (China, Japan, South Korea, Rest of Asia-Pacific)

South America

Middle East & Africa

The content of the study subjects, includes a total of 8 chapters:

Chapter 1, to describe COVID-19 Inactivated Vaccine product scope, market overview, market opportunities, market driving force and market risks.

Chapter 2, to profile the top players of COVID-19 Inactivated Vaccine, with recent

developments and future plans

Chapter 3, the COVID-19 Inactivated Vaccine competitive situation, revenue and global market share of top players are analyzed emphatically by landscape contrast.

Chapter 4, to break the market size data at the region level, with key companies in the key region and COVID-19 Inactivated Vaccine market forecast, by regions, with revenue, from 2022 to 2028.

Chapter 5 and 6, to segment the market size by Type and application, with revenue and growth rate by Type, application, from 2022 to 2028.

Chapter 7 and 8, to describe COVID-19 Inactivated Vaccine research findings and conclusion, appendix and data source.

Contents

1 MARKET OVERVIEW

- 1.1 Product Overview and Scope of COVID-19 Inactivated Vaccine
- 1.2 Classification of COVID-19 Inactivated Vaccine by Type
 - 1.2.1 Overview: Global COVID-19 Inactivated Vaccine Market Size by Type: 2022 Versus 2028
 - 1.2.2 Global COVID-19 Inactivated Vaccine Revenue Market Share by Type in 2028
 - 1.2.3 In Clinical Trials
 - 1.2.4 Out-of-Clinical Trials
- 1.3 Global COVID-19 Inactivated Vaccine Market by Application
 - 1.3.1 Overview: Global COVID-19 Inactivated Vaccine Market Size by Application: 2022 Versus 2028
 - 1.3.2 Hospital
 - 1.3.3 Clinic
 - 1.3.4 Other
- 1.4 Global COVID-19 Inactivated Vaccine Market Size & Forecast
- 1.5 Market Drivers, Restraints and Trends
 - 1.5.1 COVID-19 Inactivated Vaccine Market Drivers
 - 1.5.2 COVID-19 Inactivated Vaccine Market Restraints
 - 1.5.3 COVID-19 Inactivated Vaccine Trends Analysis

2 COMPANY PROFILES

- 2.1 Inovio Pharmaceuticals
 - 2.1.1 Inovio Pharmaceuticals Details
 - 2.1.2 Inovio Pharmaceuticals Major Business
 - 2.1.3 Inovio Pharmaceuticals COVID-19 Inactivated Vaccine Product and Solutions
 - 2.1.4 Inovio Pharmaceuticals Recent Developments and Future Plans
- 2.2 Takis Biotech (Evvivax)
 - 2.2.1 Takis Biotech (Evvivax) Details
 - 2.2.2 Takis Biotech (Evvivax) Major Business
 - 2.2.3 Takis Biotech (Evvivax) COVID-19 Inactivated Vaccine Product and Solutions
 - 2.2.4 Takis Biotech (Evvivax) Recent Developments and Future Plans
- 2.3 Zydus Cadila
 - 2.3.1 Zydus Cadila Details
 - 2.3.2 Zydus Cadila Major Business
 - 2.3.3 Zydus Cadila COVID-19 Inactivated Vaccine Product and Solutions

- 2.3.4 Zydus Cadila Recent Developments and Future Plans
- 2.4 Codagenix, Inc.
 - 2.4.1 Codagenix, Inc. Details
 - 2.4.2 Codagenix, Inc. Major Business
 - 2.4.3 Codagenix, Inc. COVID-19 Inactivated Vaccine Product and Solutions
 - 2.4.4 Codagenix, Inc. Recent Developments and Future Plans
- 2.5 GeoVax, Inc.
 - 2.5.1 GeoVax, Inc. Details
 - 2.5.2 GeoVax, Inc. Major Business
 - 2.5.3 GeoVax, Inc. COVID-19 Inactivated Vaccine Product and Solutions
 - 2.5.4 GeoVax, Inc. Recent Developments and Future Plans
- 2.6 Bravovax
 - 2.6.1 Bravovax Details
 - 2.6.2 Bravovax Major Business
 - 2.6.3 Bravovax COVID-19 Inactivated Vaccine Product and Solutions
 - 2.6.4 Bravovax Recent Developments and Future Plans
- 2.7 Janssen Pharmaceutical Companies
 - 2.7.1 Janssen Pharmaceutical Companies Details
 - 2.7.2 Janssen Pharmaceutical Companies Major Business
 - 2.7.3 Janssen Pharmaceutical Companies COVID-19 Inactivated Vaccine Product and Solutions
 - 2.7.4 Janssen Pharmaceutical Companies Recent Developments and Future Plans
- 2.8 Altimune
 - 2.8.1 Altimune Details
 - 2.8.2 Altimune Major Business
 - 2.8.3 Altimune COVID-19 Inactivated Vaccine Product and Solutions
 - 2.8.4 Altimune Recent Developments and Future Plans
- 2.9 Vaxart
 - 2.9.1 Vaxart Details
 - 2.9.2 Vaxart Major Business
 - 2.9.3 Vaxart COVID-19 Inactivated Vaccine Product and Solutions
 - 2.9.4 Vaxart Recent Developments and Future Plans
- 2.10 CanSino Biologics
 - 2.10.1 CanSino Biologics Details
 - 2.10.2 CanSino Biologics Major Business
 - 2.10.3 CanSino Biologics COVID-19 Inactivated Vaccine Product and Solutions
 - 2.10.4 CanSino Biologics Recent Developments and Future Plans
- 2.11 ExpreS2ion Biotechnologies ApS
 - 2.11.1 ExpreS2ion Biotechnologies ApS Details

- 2.11.2 ExpreS2ion Biotechnologies ApS Major Business
- 2.11.3 ExpreS2ion Biotechnologies ApS COVID-19 Inactivated Vaccine Product and Solutions
- 2.11.4 ExpreS2ion Biotechnologies ApS Recent Developments and Future Plans
- 2.12 Clover Biopharmaceuticals
 - 2.12.1 Clover Biopharmaceuticals Details
 - 2.12.2 Clover Biopharmaceuticals Major Business
 - 2.12.3 Clover Biopharmaceuticals COVID-19 Inactivated Vaccine Product and Solutions
 - 2.12.4 Clover Biopharmaceuticals Recent Developments and Future Plans
- 2.13 GSK
 - 2.13.1 GSK Details
 - 2.13.2 GSK Major Business
 - 2.13.3 GSK COVID-19 Inactivated Vaccine Product and Solutions
 - 2.13.4 GSK Recent Developments and Future Plans
- 2.14 Vaxil Bio Ltd.
 - 2.14.1 Vaxil Bio Ltd. Details
 - 2.14.2 Vaxil Bio Ltd. Major Business
 - 2.14.3 Vaxil Bio Ltd. COVID-19 Inactivated Vaccine Product and Solutions
 - 2.14.4 Vaxil Bio Ltd. Recent Developments and Future Plans
- 2.15 Generex
 - 2.15.1 Generex Details
 - 2.15.2 Generex Major Business
 - 2.15.3 Generex COVID-19 Inactivated Vaccine Product and Solutions
 - 2.15.4 Generex Recent Developments and Future Plans
- 2.16 Novavax, Inc.
 - 2.16.1 Novavax, Inc. Details
 - 2.16.2 Novavax, Inc. Major Business
 - 2.16.3 Novavax, Inc. COVID-19 Inactivated Vaccine Product and Solutions
 - 2.16.4 Novavax, Inc. Recent Developments and Future Plans
- 2.17 Sanofi Pasteur
 - 2.17.1 Sanofi Pasteur Details
 - 2.17.2 Sanofi Pasteur Major Business
 - 2.17.3 Sanofi Pasteur COVID-19 Inactivated Vaccine Product and Solutions
 - 2.17.4 Sanofi Pasteur Recent Developments and Future Plans
- 2.18 Baylor
 - 2.18.1 Baylor Details
 - 2.18.2 Baylor Major Business
 - 2.18.3 Baylor COVID-19 Inactivated Vaccine Product and Solutions

- 2.18.4 Baylor Recent Developments and Future Plans
- 2.19 iBio, Inc.
 - 2.19.1 iBio, Inc. Details
 - 2.19.2 iBio, Inc. Major Business
 - 2.19.3 iBio, Inc. COVID-19 Inactivated Vaccine Product and Solutions
 - 2.19.4 iBio, Inc. Recent Developments and Future Plans
- 2.20 Moderna, Inc.
 - 2.20.1 Moderna, Inc. Details
 - 2.20.2 Moderna, Inc. Major Business
 - 2.20.3 Moderna, Inc. COVID-19 Inactivated Vaccine Product and Solutions
 - 2.20.4 Moderna, Inc. Recent Developments and Future Plans
- 2.21 Curevac
 - 2.21.1 Curevac Details
 - 2.21.2 Curevac Major Business
 - 2.21.3 Curevac COVID-19 Inactivated Vaccine Product and Solutions
 - 2.21.4 Curevac Recent Developments and Future Plans
- 2.22 ImmunoPrecise
 - 2.22.1 ImmunoPrecise Details
 - 2.22.2 ImmunoPrecise Major Business
 - 2.22.3 ImmunoPrecise COVID-19 Inactivated Vaccine Product and Solutions
 - 2.22.4 ImmunoPrecise Recent Developments and Future Plans

3 MARKET COMPETITION, BY PLAYERS

- 3.1 Global COVID-19 Inactivated Vaccine Revenue and Share by Players (2022 & 2028)
- 3.2 COVID-19 Inactivated Vaccine Players Head Office, Products and Services Provided
- 3.3 COVID-19 Inactivated Vaccine Mergers & Acquisitions
- 3.4 COVID-19 Inactivated Vaccine New Entrants and Expansion Plans

4 GLOBAL COVID-19 INACTIVATED VACCINE FORECAST BY REGION

- 4.1 Global COVID-19 Inactivated Vaccine Market Size by Region: 2022 VS 2028
- 4.2 Global COVID-19 Inactivated Vaccine Market Size by Region, (2022-2028)
- 4.3 North America
 - 4.3.1 Key Companies of COVID-19 Inactivated Vaccine in North America
 - 4.3.2 Current Situation and Forecast of COVID-19 Inactivated Vaccine in North America

4.3.3 North America COVID-19 Inactivated Vaccine Market Size and Prospect
(2022-2028)

4.4 Europe

4.4.1 Key Companies of COVID-19 Inactivated Vaccine in Europe

4.4.2 Current Situation and Forecast of COVID-19 Inactivated Vaccine in Europe

4.4.3 Europe COVID-19 Inactivated Vaccine Market Size and Prospect (2022-2028)

4.5 Asia-Pacific

4.5.1 Key Companies of COVID-19 Inactivated Vaccine in Asia-Pacific

4.5.2 Current Situation and Forecast of COVID-19 Inactivated Vaccine in Asia-Pacific

4.5.3 Asia-Pacific COVID-19 Inactivated Vaccine Market Size and Prospect
(2022-2028)

4.6 South America

4.6.1 Key Companies of COVID-19 Inactivated Vaccine in South America

4.6.2 Current Situation and Forecast of COVID-19 Inactivated Vaccine in South
America

4.6.3 South America COVID-19 Inactivated Vaccine Market Size and Prospect
(2022-2028)

4.7 Middle East & Africa

4.7.1 Key Companies of COVID-19 Inactivated Vaccine in Middle East & Africa

4.7.2 Current Situation and Forecast of COVID-19 Inactivated Vaccine in Middle East
& Africa

4.7.3 Middle East & Africa COVID-19 Inactivated Vaccine Market Size and Prospect
(2022-2028)

5 MARKET SIZE SEGMENT BY TYPE

5.1 Global COVID-19 Inactivated Vaccine Market Forecast by Type (2022-2028)

5.2 Global COVID-19 Inactivated Vaccine Market Share Forecast by Type (2022-2028)

6 MARKET SIZE SEGMENT BY APPLICATION

6.1 Global COVID-19 Inactivated Vaccine Market Forecast by Application (2022-2028)

6.2 Global COVID-19 Inactivated Vaccine Market Share Forecast by Application
(2022-2028)

7 RESEARCH FINDINGS AND CONCLUSION

8 APPENDIX

8.1 Methodology

8.2 Research Process and Data Source

8.3 Disclaimer

List Of Tables

LIST OF TABLES

Table 1. Global COVID-19 Inactivated Vaccine Revenue by Type, (USD Million), 2022 VS 2028

Table 2. Global COVID-19 Inactivated Vaccine Revenue by Application, (USD Million), 2022 VS 2028

Table 3. Inovio Pharmaceuticals Corporate Information, Head Office, and Major Competitors

Table 4. Inovio Pharmaceuticals Major Business

Table 5. Inovio Pharmaceuticals COVID-19 Inactivated Vaccine Product and Solutions

Table 6. Takis Biotech (Evvivax) Corporate Information, Head Office, and Major Competitors

Table 7. Takis Biotech (Evvivax) Major Business

Table 8. Takis Biotech (Evvivax) COVID-19 Inactivated Vaccine Product and Solutions

Table 9. Zydus Cadila Corporate Information, Head Office, and Major Competitors

Table 10. Zydus Cadila Major Business

Table 11. Zydus Cadila COVID-19 Inactivated Vaccine Product and Solutions

Table 12. Codagenix, Inc. Corporate Information, Head Office, and Major Competitors

Table 13. Codagenix, Inc. Major Business

Table 14. Codagenix, Inc. COVID-19 Inactivated Vaccine Product and Solutions

Table 15. GeoVax, Inc. Corporate Information, Head Office, and Major Competitors

Table 16. GeoVax, Inc. Major Business

Table 17. GeoVax, Inc. COVID-19 Inactivated Vaccine Product and Solutions

Table 18. Bravovax Corporate Information, Head Office, and Major Competitors

Table 19. Bravovax Major Business

Table 20. Bravovax COVID-19 Inactivated Vaccine Product and Solutions

Table 21. Janssen Pharmaceutical Companies Corporate Information, Head Office, and Major Competitors

Table 22. Janssen Pharmaceutical Companies Major Business

Table 23. Janssen Pharmaceutical Companies COVID-19 Inactivated Vaccine Product and Solutions

Table 24. Altimune Corporate Information, Head Office, and Major Competitors

Table 25. Altimune Major Business

Table 26. Altimune COVID-19 Inactivated Vaccine Product and Solutions

Table 27. Vaxart Corporate Information, Head Office, and Major Competitors

Table 28. Vaxart Major Business

Table 29. Vaxart COVID-19 Inactivated Vaccine Product and Solutions

Table 30. CanSino Biologics Corporate Information, Head Office, and Major Competitors

Table 31. CanSino Biologics Major Business

Table 32. CanSino Biologics COVID-19 Inactivated Vaccine Product and Solutions

Table 33. ExpreS2ion Biotechnologies ApS Corporate Information, Head Office, and Major Competitors

Table 34. ExpreS2ion Biotechnologies ApS Major Business

Table 35. ExpreS2ion Biotechnologies ApS COVID-19 Inactivated Vaccine Product and Solutions

Table 36. Clover Biopharmaceuticals Corporate Information, Head Office, and Major Competitors

Table 37. Clover Biopharmaceuticals Major Business

Table 38. Clover Biopharmaceuticals COVID-19 Inactivated Vaccine Product and Solutions

Table 39. GSK Corporate Information, Head Office, and Major Competitors

Table 40. GSK Major Business

Table 41. GSK COVID-19 Inactivated Vaccine Product and Solutions

Table 42. Vaxil Bio Ltd. Corporate Information, Head Office, and Major Competitors

Table 43. Vaxil Bio Ltd. Major Business

Table 44. Vaxil Bio Ltd. COVID-19 Inactivated Vaccine Product and Solutions

Table 45. Generex Corporate Information, Head Office, and Major Competitors

Table 46. Generex Major Business

Table 47. Generex COVID-19 Inactivated Vaccine Product and Solutions

Table 48. Novavax, Inc. Corporate Information, Head Office, and Major Competitors

Table 49. Novavax, Inc. Major Business

Table 50. Novavax, Inc. COVID-19 Inactivated Vaccine Product and Solutions

Table 51. Sanofi Pasteur Corporate Information, Head Office, and Major Competitors

Table 52. Sanofi Pasteur Major Business

Table 53. Sanofi Pasteur COVID-19 Inactivated Vaccine Product and Solutions

Table 54. Baylor Corporate Information, Head Office, and Major Competitors

Table 55. Baylor Major Business

Table 56. Baylor COVID-19 Inactivated Vaccine Product and Solutions

Table 57. iBio, Inc. Corporate Information, Head Office, and Major Competitors

Table 58. iBio, Inc. Major Business

Table 59. iBio, Inc. COVID-19 Inactivated Vaccine Product and Solutions

Table 60. Moderna, Inc. Corporate Information, Head Office, and Major Competitors

Table 61. Moderna, Inc. Major Business

Table 62. Moderna, Inc. COVID-19 Inactivated Vaccine Product and Solutions

Table 63. Curevac Corporate Information, Head Office, and Major Competitors

Table 64. Curevac Major Business

Table 65. Curevac COVID-19 Inactivated Vaccine Product and Solutions

Table 66. ImmunoPrecise Corporate Information, Head Office, and Major Competitors

Table 67. ImmunoPrecise Major Business

Table 68. ImmunoPrecise COVID-19 Inactivated Vaccine Product and Solutions

Table 69. Global COVID-19 Inactivated Vaccine Revenue (USD Million) by Players (2022 & 2028)

Table 70. Global COVID-19 Inactivated Vaccine Revenue Share by Players (2022 & 2028)

Table 71. COVID-19 Inactivated Vaccine Players Head Office, Products and Services Provided

Table 72. COVID-19 Inactivated Vaccine Mergers & Acquisitions in the Past Five Years

Table 73. COVID-19 Inactivated Vaccine New Entrants and Expansion Plans

Table 74. Global Market COVID-19 Inactivated Vaccine Revenue (USD Million) Comparison by Region (2022 VS 2028)

Table 75. Global COVID-19 Inactivated Vaccine Revenue Market Share by Region (2022-2028)

Table 76. Key Companies of COVID-19 Inactivated Vaccine in North America

Table 77. Current Situation and Forecast of COVID-19 Inactivated Vaccine in North America

Table 78. Key Companies of COVID-19 Inactivated Vaccine in Europe

Table 79. Current Situation and Forecast of COVID-19 Inactivated Vaccine in Europe

Table 80. Key Companies of COVID-19 Inactivated Vaccine in Asia-Pacific

Table 81. Current Situation and Forecast of COVID-19 Inactivated Vaccine in Asia-Pacific

Table 82. Key Companies of COVID-19 Inactivated Vaccine in China

Table 83. Key Companies of COVID-19 Inactivated Vaccine in Japan

Table 84. Key Companies of COVID-19 Inactivated Vaccine in South Korea

Table 85. Key Companies of COVID-19 Inactivated Vaccine in South America

Table 86. Current Situation and Forecast of COVID-19 Inactivated Vaccine in South America

Table 87. Key Companies of COVID-19 Inactivated Vaccine in Middle East & Africa

Table 88. Current Situation and Forecast of COVID-19 Inactivated Vaccine in Middle East & Africa

Table 89. Global COVID-19 Inactivated Vaccine Revenue Forecast by Type (2022-2028)

Table 90. Global COVID-19 Inactivated Vaccine Revenue Forecast by Application (2022-2028)

List Of Figures

LIST OF FIGURES

- Figure 1. COVID-19 Inactivated Vaccine Picture
- Figure 2. Global COVID-19 Inactivated Vaccine Revenue Market Share by Type in 2028
- Figure 3. In Clinical Trials
- Figure 4. Out-of-Clinical Trials
- Figure 5. COVID-19 Inactivated Vaccine Revenue Market Share by Application in 2028
- Figure 6. Hospital Picture
- Figure 7. Clinic Picture
- Figure 8. Other Picture
- Figure 9. Global COVID-19 Inactivated Vaccine Market Size, (USD Million): 2022 VS 2028
- Figure 10. Global COVID-19 Inactivated Vaccine Revenue and Forecast (2022-2028) & (USD Million)
- Figure 11. COVID-19 Inactivated Vaccine Market Drivers
- Figure 12. COVID-19 Inactivated Vaccine Market Restraints
- Figure 13. COVID-19 Inactivated Vaccine Market Trends
- Figure 14. Inovio Pharmaceuticals Recent Developments and Future Plans
- Figure 15. Takis Biotech (Evvivax) Recent Developments and Future Plans
- Figure 16. Zydus Cadila Recent Developments and Future Plans
- Figure 17. Codagenix, Inc. Recent Developments and Future Plans
- Figure 18. GeoVax, Inc. Recent Developments and Future Plans
- Figure 19. Bravovax Recent Developments and Future Plans
- Figure 20. Janssen Pharmaceutical Companies Recent Developments and Future Plans
- Figure 21. Altimune Recent Developments and Future Plans
- Figure 22. Vaxart Recent Developments and Future Plans
- Figure 23. CanSino Biologics Recent Developments and Future Plans
- Figure 24. ExpreS2ion Biotechnologies ApS Recent Developments and Future Plans
- Figure 25. Clover Biopharmaceuticals Recent Developments and Future Plans
- Figure 26. GSK Recent Developments and Future Plans
- Figure 27. Vaxil Bio Ltd. Recent Developments and Future Plans
- Figure 28. Generex Recent Developments and Future Plans
- Figure 29. Novavax, Inc. Recent Developments and Future Plans
- Figure 30. Sanofi Pasteur Recent Developments and Future Plans
- Figure 31. Baylor Recent Developments and Future Plans
- Figure 32. iBio, Inc. Recent Developments and Future Plans

Figure 33. Moderna, Inc. Recent Developments and Future Plans

Figure 34. Curevac Recent Developments and Future Plans

Figure 35. ImmunoPrecise Recent Developments and Future Plans

Figure 36. Global COVID-19 Inactivated Vaccine Revenue Market Share by Region (2022-2028)

Figure 37. Global COVID-19 Inactivated Vaccine Revenue Market Share by Region in 2028

Figure 38. North America COVID-19 Inactivated Vaccine Revenue (USD Million) and Growth Rate (2022-2028)

Figure 39. Europe COVID-19 Inactivated Vaccine Revenue (USD Million) and Growth Rate (2022-2028)

Figure 40. Asia-Pacific COVID-19 Inactivated Vaccine Revenue (USD Million) and Growth Rate (2022-2028)

Figure 41. South America COVID-19 Inactivated Vaccine Revenue (USD Million) and Growth Rate (2022-2028)

Figure 42. Middle East & Africa COVID-19 Inactivated Vaccine Revenue (USD Million) and Growth Rate (2022-2028)

Figure 43. Global COVID-19 Inactivated Vaccine Market Share Forecast by Type (2022-2028)

Figure 44. Global COVID-19 Inactivated Vaccine Market Share Forecast by Application (2022-2028)

Figure 45. Methodology

Figure 46. Research Process and Data Source

I would like to order

Product name: Global COVID-19 Inactivated Vaccine Market 2022 by Company, Regions, Type and Application, Forecast to 2028

Product link: <https://marketpublishers.com/r/GA5C7FA4A77DEN.html>

Price: US\$ 3,480.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/GA5C7FA4A77DEN.html>